References
- Okhravi N, Odufuwa B, McCluskey P, et al. Scleritis. Surv Ophthalmol. 2005;50(4):351–363.
- Beardsley RM, Suhler EB, Rosenbaum JT, et al. Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother. 2013;14(4):411–424.
- Akpek EK, Thorne JE, Qazi FA, et al. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111(3):501–506.
- Raiji VR, Palestine AG, Parver DL. Scleritis and systemic disease association in a community-based referral practice. Am J Ophthalmol. 2009;148(6):946–950.
- Watson PG, Young RD. Scleral structure, organisation and disease. A review. Exp Eye Res. 2004;78(3):609–623.
- Jia X, Yu J, Liao SH, et al. Biomechanics of the sclera and effects on intraocular pressure. Int J Ophthalmol. 2016;9(12):1824–1831.
- Keeley FW, Morin JD, Vesely S. Characterization of collagen from normal human sclera. Exp Eye Res. 1984;39(5):533–542.
- Komai Y, Ushiki T. The three-dimensional organization of collagen fibrils in the human cornea and sclera. Invest Ophthalmol Vis Sci. 1991;32(8):2244–2258.
- Wang B, Hua Y, Brazile BL, et al. Collagen fiber interweaving is central to sclera stiffness. Acta Biomater. 2020;113:429–437.
- Boote C, Sigal IA, Grytz R, et al. Scleral structure and biomechanics. Prog Retin Eye Res. 2020;74:100773.
- Rada JA, Achen VR, Penugonda S, et al. Proteoglycan composition in the human sclera during growth and aging. Invest Ophthalmol Vis Sci. 2000;41(7):1639–1648.
- Hu DN, Yao S, Iacob CE, et al. Quantitative study of human scleral melanocytes and their topographical distribution. Curr Eye Res. 2020;45(12):1563–1571.
- Snell R, Lemp M. Clinical anatomy of the eye. Cambridge, MA: Blackwell Scientific Publications; 1989. p. 125–126.
- Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60(3):163–191.
- Smith JR, Mackensen F, Rosenbaum JT. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol. 2007;3(4):219–226.
- Honik G, Wong IG, Gritz DC. Incidence and prevalence of episcleritis and scleritis in Northern California. Cornea. 2013;32(12):1562–1566.
- Homayounfar G, Nardone N, Borkar DS, et al. Incidence of scleritis and episcleritis: results from the pacific ocular inflammation study. Am J Ophthalmol. 2013;156(4):752–758.
- Xu TT, Reynolds MM, Hodge DO, et al. Epidemiology and clinical characteristics of episcleritis and scleritis in Olmsted county, minnesota. Am J Ophthalmol. 2020;217:317–324.
- Zhang Y, Amin S, Lung KI, et al. Incidence, prevalence, and risk factors of infectious uveitis and scleritis in the United States: a claims-based analysis. PLoS One. 2020;15(8):e0237995.
- Sainz de la Maza M, Jabbur NS, Foster CS. Severity of scleritis and episcleritis. Ophthalmology. 1994;101(2):389–396.
- Hodson KL, Galor A, Karp CL, et al. Epidemiology and visual outcomes in patients with infectious scleritis. Cornea. 2013;32(4):466–472.
- Leung TG, Dunn JP, Akpek EK, et al. Necrotizing scleritis as a complication of cosmetic eye whitening procedure. J Ophthalmic Inflamm Infect. 2013;3(1):39.
- Sainz de la Maza M, Foster CS. Necrotizing scleritis after ocular surgery. A clinicopathologic study. Ophthalmology. 1991;98(11):1720–1726.
- Sainz de la Maza M, Hemady RK, Foster CS. Infectious scleritis: report of four cases. Doc Ophthalmol. 1993;83(1):33–41.
- Jabs DA, Mudun A, Dunn JP, et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469–476.
- Rich RM, Smiddy WE, Davis JL. Infectious scleritis after retinal surgery. Am J Ophthalmol. 2008;145(4):695–699.
- Smith JR, Chee SP. Nodular anterior scleritis associated with ocular trauma. Singapore Med J. 2001;42(4):180–181.
- Smith LK, Suhler EB, Lim LL, et al. Possible association between scleritis and lymphoma. Br J Ophthalmol. 2007;91(12):1728–1729.
- Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. CMAJ. 2012;184(8):E431–4.
- Misawa N, Tagami M, Sakai A, et al. Rapid regression of scleral melting associated with tumor necrosis factor-alpha in a case of surgically induced necrotizing scleritis. Case Rep Ophthalmol. 2020;11(2):418–422.
- Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119(1):43–50.
- McGavin DD, Williamson J, Forrester JV, et al. Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophthalmol. 1976;60(3):192–226.
- Berkenstock MK, Carey AR. Health system wide “big data” analysis of rheumatologic conditions and scleritis. BMC Ophthalmol. 2021;21(1):14.
- Cheung CM, Chee SP. Posterior scleritis in children: clinical features and treatment. Ophthalmology. 2012;119(1):59–65.
- Ramenaden ER, Raiji VR. Clinical characteristics and visual outcomes in infectious scleritis: a review. Clin Ophthalmol. 2013;7:2113–2122.
- Jain V, Garg P, Sharma S. Microbial scleritis-experience from a developing country. Eye (Lond). 2009;23(2):255–261.
- Bhat PV, Jakobiec FA, Kurbanyan K, et al. Chronic herpes simplex scleritis: characterization of 9 cases of an underrecognized clinical entity. Am J Ophthalmol. 2009;148(5):779–89 e2.
- Artifoni M, Rothschild PR, Brezin A, et al. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(2):108–116.
- Lagina A, Ramphul K. Scleritis. Treasure Island (FL): StatPearls Publishing; 2021 Jan:1-11.
- Di Girolamo N, Lloyd A, McCluskey P, et al. Increased expression of matrix metalloproteinases in vivo in scleritis tissue and in vitro in cultured human scleral fibroblasts. Am J Pathol. 1997;150(2):653–666.
- Fong LP, Sainz de la Maza M, Ba R, et al. Immunopathology of scleritis. Ophthalmology. 1991;98(4):472–479.
- Riono WP, Hidayat AA, Rao NA. Scleritis: a clinicopathologic study of 55 cases. Ophthalmology. 1999;106(7):1328–1333.
- Benson WE. Posterior scleritis. Surv Ophthalmol. 1988;32(5):297–316.
- McCluskey PJ, Watson PG, Lightman S, et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999;106(12):2380–2386.
- Watson PG, Bovey E. Anterior segment fluorescein angiography in the diagnosis of scleral inflammation. Ophthalmology. 1985;92(1):1–11.
- Ando Y, Keino H, Nakayama M, et al. Clinical features, treatment, and visual outcomes of Japanese patients with posterior scleritis. Ocul Immunol Inflamm. 2020;28(2):209–216.
- Calthorpe CM, Watson PG, McCartney AC. Posterior scleritis: a clinical and histological survey. Eye (Lond). 1988;2(Pt 3):267–277.
- Munk P, Nicolle D, Downey D, et al. Posterior scleritis: ultrasound and clinical findings. Can J Ophthalmol. 1993;28(4):177–180.
- Biswas J, Mittal S, Ganesh SK, et al. Posterior scleritis: clinical profile and imaging characteristics. Indian J Ophthalmol. 1998;46(4):195–202.
- Cordero-Coma M, Garcia-Moran A, Yilmaz T, et al. Adjunctive globe magnetic resonance imaging in the diagnosis of posterior scleritis. Can J Ophthalmol. 2011;46(4):329–332.
- Taki W, Keino H, Watanabe T, et al. Enhanced depth imaging optical coherence tomography of the choroid in recurrent unilateral posterior scleritis. Graefes Arch Clin Exp Ophthalmol. 2013;251(3):1003–1004.
- Hirukawa K, Keino H, Watanabe T, et al. Enhanced depth imaging optical coherence tomography of the choroid in new-onset acute posterior scleritis. Graefes Arch Clin Exp Ophthalmol. 2013;251(9):2273–2275.
- Auer C, Herbort CP. Indocyanine green angiographic features in posterior scleritis. Am J Ophthalmol. 1998;126(3):471–476.
- Alsarhani WK, Abu El-Asrar AM. Multimodal imaging of nodular posterior scleritis: case report and review of the literature. Middle East Afr J Ophthalmol. 2020;27(2):134–138.
- Murthy SI, Sabhapandit S, Balamurugan S, et al. Scleritis: differentiating infectious from non-infectious entities. Indian J Ophthalmol. 2020;68(9):1818–1828.
- Ho YF, Yeh LK, Tan HY, et al. Infectious scleritis in Taiwan-a 10-year review in a tertiary-care hospital. Cornea. 2014;33(8):838–843.
- McCluskey P, Wakefield D. Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol. 1991;19(3):211–215.
- Sen HN, Sangave AA, Goldstein DA, et al. A standardized grading system for scleritis. Ophthalmology. 2011;118(4):768–771.
- Guex-Crosier Y, Durig J. Anterior segment indocyanine green angiography in anterior scleritis and episcleritis. Ophthalmology. 2003;110(9):1756–1763.
- Nieuwenhuizen J, Watson PG, Jager MJ, et al. The value of combining anterior segment fluorescein angiography with indocyanine green angiography in scleral inflammation. Ophthalmology. 2003;110(8):1653–1666.
- Watson P, Romano A. The impact of new methods of investigation and treatment on the understanding of the pathology of scleral inflammation. Eye (Lond). 2014;28(8):915–930.
- Ogra S, Sims JL, McGhee CNJ, et al. Ocular complications and mortality in peripheral ulcerative keratitis and necrotising scleritis: the role of systemic immunosuppression. Clin Exp Ophthalmol. 2020;48(4):434–441.
- McMullen M, Kovarik G, Hodge WG. Use of topical steroid therapy in the management of nonnecrotizing anterior scleritis. Can J Ophthalmol. 1999;34(4):217–221.
- Sohn EH, Wang R, Read R, et al. Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis. Ophthalmology. 2011;118(10):1932–1937.
- Nascimento H, Franca M, Garcia LG, et al. Subconjunctival dexamethasone implant for non-necrotizing scleritis. J Ophthalmic Inflamm Infect. 2013;3(1):7.
- Eslampour A, Abrishami M, Tafaghodi S. Conjunctival necrosis and scleritis following subtenon triamcinolone acetonide injection. Iran Red Crescent Med J. 2013;15(7):614–616.
- Watson PG. The diagnosis and management of scleritis. Ophthalmology. 1980;87(7):716–720.
- Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Scleritis therapy. Ophthalmology. 2012;119(1):51–58.
- Foster CS. Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology. 1980;87(2):140–150.
- Jachens AW, Chu DS. Retrospective review of methotrexate therapy in the treatment of chronic, noninfectious, nonnecrotizing scleritis. Am J Ophthalmol. 2008;145(3):487–492.
- Kolomeyer AM, Ragam A, Shah K, et al. Mycophenolate mofetil in the treatment of chronic non-infectious, non-necrotizing scleritis. Ocul Immunol Inflamm. 2012;20(2):113–118.
- Sen HN, Suhler EB, Al-Khatib SQ, et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology. 2003;110(9):1750–1755.
- Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.
- Sainz de la Maza M, Jabbur NS, Foster CS. An analysis of therapeutic decision for scleritis. Ophthalmology. 1993;100(9):1372–1376.
- Tuft SJ, Watson PG. Progression of scleral disease. Ophthalmology. 1991;98(4):467–471.
- Helm CJ, Holland GN, Webster RG Jr., et al. Combination intravenous ceftazidime and aminoglycosides in the treatment of pseudomonal scleritis. Ophthalmology. 1997;104(5):838–843.
- Guerrero-Wooley RL, Peacock JE Jr. Infectious scleritis: what the ID clinician should know. Open Forum Infect Dis. 2018;5(6):ofy140.
- Dutta Majumder PA, Agrawal R, McCluskey P, et al. Current approach for the diagnosis and management of noninfective scleritis. Asia Pac J Ophthalmol (Phila). 2020 Dec 7;10(2):212–223.
- Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, et al. Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35 cases. Ophthalmology. 2012;119(7):1460–1464.
- Bernauer W, Allan BD, Dart JK. Successful management of Aspergillus scleritis by medical and surgical treatment. Eye (Lond). 1998;12(Pt 2):311–316.
- Brunette I, Stulting RD. Sporothrix schenckii scleritis. Am J Ophthalmol. 1992;114(3):370–371.
- Kedhar SR. Scleritis and peripheral ulcerative keratitis with hepatitis C Virus–Related cryoglobulinemia. Arch Ophthalmol. 2007;125(6):852–853.
- Alsagoff Z, Tan DT, Chee SP. Necrotising scleritis after bare sclera excision of pterygium. Br J Ophthalmol. 2000;84(9):1050–1052.
- Pujari A, Chaniyara MH, Sharma P, et al. Necrotizing scleritis following uncomplicated strabismus surgery. Indian J Ophthalmol. 2020;68(11):2555–2557.
- Kremer JM. Methotrexate and emerging therapies. Clin Exp Rheumatol. 1999;17(6 Suppl 18):S43–6.
- Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea. 1995;14(4):408–417.
- Kaplan-Messas A, Barkana Y, Avni I, et al. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11(2):131–139.
- Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984;91(10):1253–1263.
- Hiyama T, Harada Y, Kiuchi Y. Clinical characteristics and efficacy of methotrexate in Japanese patients with noninfectious scleritis. Jpn J Ophthalmol. 2021;65(1):97–106.
- Mohan S SP, Khalid KHM, Khalid KHM. Anti-neutrophil cytoplasmic antibody (ANCA)-associated scleritis: a diagnostic challenge and outcome. The Egyptian Rheumatologist. 2020;42(1):79–82
- Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–1832.
- Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9 e2.
- Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89(4):227–235.
- Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416–21, 21 e1.
- Alldred A, Emery P. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2001;2(1):125–137.
- Steigerwalt RD Jr., Bacci S, Valesini G. Severe uveitis successfully treated with leflunomide. Retin Cases Brief Rep. 2007;1(1):54–55.
- Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 1984;77(4):652–656.
- Hakin KN, Ham J, Lightman SL. Use of cyclosporin in the management of steroid dependent non-necrotising scleritis. Br J Ophthalmol. 1991;75(6):340–341.
- Wakefield D, McCluskey P. Cyclosporin therapy for severe scleritis. Br J Ophthalmol. 1989;73(9):743–746.
- Hillenkamp J, Kersten A, Althaus C, et al. [Cyclosporin A therapy in severe anterior scleritis. 5 severe courses without verification of associated systemic disease treated with cyclosporin A]. Ophthalmologe. 2000;97(12):863–869.
- Daniell MD, Dart JK, Lightman S. Use of cyclosporin in the treatment of steroid resistant post-keratoplasty atopic sclerokeratitis. Br J Ophthalmol. 2001;85(1):91–92.
- Young AL, Wong SM, Leung AT, et al. Successful treatment of surgically induced necrotizing scleritis with tacrolimus. Clin Exp Ophthalmol. 2005;33(1):98–99.
- Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res. 2019;61(1):44–50.
- Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109(2):370–377.
- Shoughy SS, Jaroudi MO, Kozak I, et al. Optical coherence tomography in the diagnosis of scleritis and episcleritis. Am J Ophthalmol. 2015;159(6):1045–9 e1.
- Levison AL, Lowder CY, Baynes KM, et al. Anterior segment spectral domain optical coherence tomography imaging of patients with anterior scleritis. Int Ophthalmol. 2016;36(4):499–508.
- Axmann S, Ebneter A, Zinkernagel MS. Imaging of the sclera in patients with scleritis and episcleritis using anterior segment optical coherence tomography. Ocul Immunol Inflamm. 2016;24(1):29–34.
- Akhavanrezayat AHM, Onghanseng NL. Longitudinal assessment of patients with anterior scleritis using scleral area vessel density. Invest Ophthalmol Vis Sci. 2020;61(7):4825–4848. 25.
- Lee WD, Devarajan K, Chua J, et al. Optical coherence tomography angiography for the anterior segment. Eye Vis (Lond). 2019;6:4.
- Hau SC, Devarajan K, Ang M. Anterior segment optical coherence tomography angiography and optical coherence tomography in the evaluation of episcleritis and scleritis. Ocul Immunol Inflamm. 2021;29(2):362-369.
- Pavlin CJ, Easterbrook M, Hurwitz JJ, et al. Ultrasound biomicroscopy in the assessment of anterior scleral disease. Am J Ophthalmol. 1993;116(5):628–635.
- Zur D, Neudorfer M, Shulman S, et al. High-resolution ultrasound biomicroscopy as an adjunctive diagnostic tool for anterior scleral inflammatory disease. Acta Ophthalmol. 2016;94(6):e384–9.
- Heiligenhaus A, Schilling M, Lung E, et al. Ultrasound biomicroscopy in scleritis. Ophthalmology. 1998;105(3):527–534.
- Kawali AA. Thermography in ocular inflammation. Indian J Radiol Imaging. 2013;23(3):281–283.
- Chan CM, Chew PT, Alsagoff Z, et al. Vascular patterns in pterygium and conjunctival autografting: a pilot study using indocyanine green anterior segment angiography. Br J Ophthalmol. 2001;85(3):350–353.
- Lavric A, Gonzalez-Lopez JJ, Majumder PD, et al. Posterior scleritis: analysis of epidemiology, clinical factors, and risk of recurrence in a cohort of 114 patients. Ocul Immunol Inflamm. 2016;24(1):6–15.
- Grosso D, Borrelli E, Sacconi R, et al. Recognition, diagnosis and treatment of chorioretinal folds: current perspectives. Clin Ophthalmol. 2020;14:3403–3409.
- Bhatt N, Dalal M, Tucker W, et al. Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial. Am J Ophthalmol. 2015;159(3):601–606.
- Yazu H, Miyazaki D, Fujishima H. Experience with 0.1% tacrolimus eye drop for noninfectious, non-necrotizing anterior scleritis. Eye Contact Lens. 2021;47(4):185-190.
- Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology. 2008;115(6):988–92 e5.
- Feizi S, Javadi MA. Topical erythropoietin as a novel treatment for necrotizing scleritis after pterygium surgery: a pilot study. Cornea. 2021;40(8):1011-1017.
- Feizi S, Alemzadeh-Ansari M, Baradaran-Rafii A, et al. 1Topical erythropoietin for treatment of scleral necrosis. Ocul Immunol Inflamm. 2021;1–6. doi: https://doi.org/10.1080/09273948.2021.1934485
- Behar-Cohen FF, Parel JM, Pouliquen Y, et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res. 1997;65(4):533–545.
- Cohen AE, Assang C, Patane MA, et al. Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology. 2012;119(1):66–73.
- O’Neil EC, Huang J, Suhler EB, et al. Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial. Br J Ophthalmol. 2018;102(8):1011–1013.
- Zhao YJ, Zou YL, Lu Y, et al. Intravitreal dexamethasone implant - a new treatment for idiopathic posterior scleritis: a case report. World J Clin Cases. 2021;9(2):422–428.
- Syed ZA, Rapuano CJ. Umbilical amnion and amniotic membrane transplantation for infectious scleritis and scleral melt: a case series. Am J Ophthalmol Case Rep. 2021;21:101013.
- Fabiani C, Sota J, Sainz-de-la-Maza M, et al. Effectiveness of TNF-alpha blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clin Exp Rheumatol. 2020;38(6):1138–1144.
- Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480.
- Sen HN, Sangave A, Hammel K, et al. Infliximab for the treatment of active scleritis. Can J Ophthalmol. 2009;44(3):e9–e12.
- Khalili S, Mireskandari K. Infliximab for management of severe refractory posterior scleritis in a 9-year-old boy. Can J Ophthalmol. 2021;56(3):92-94.
- Ragam A, Kolomeyer AM, Fang C, et al. Treatment of chronic, noninfectious, nonnecrotizing scleritis with tumor necrosis factor alpha inhibitors. Ocul Immunol Inflamm. 2014;22(6):469–477.
- Sadhu S, Dutta Majumder P, Biswas J. Biological therapy in refractory cases of uveitis and scleritis: an analysis of 18 cases from a tertiary eye care center from South India. Indian J Ophthalmol. 2020;68(9):1929–1933.
- Doctor P, Sultan A, Syed S, et al. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94(5):579–583.
- El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener’s granulomatosis. Eye (Lond). 2005;19(9):1017–1018.
- Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45(3):252–257.
- Sobrin L, Kim EC, Christen W, et al. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol. 2007;125(7):895–900.
- Ahn SJ, Oh JY, Kim MK, et al. Treating refractory scleritis with infliximab. Jpn J Ophthalmol. 2009;53(3):286–287.
- Taban M, Dupps WJ, Mandell B, et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. 2006;14(3):145–150.
- Hernandez-Illas M, Tozman E, Fulcher SF, et al. Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens. 2004;30(1):2–5.
- Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192.
- Lawuyi LE, Gurbaxani A. Refractory necrotizing scleritis successfully treated with Adalimumab. J Ophthalmic Inflamm Infect. 2016;6(1):37.
- Bawazeer AM, Raffa LH. Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis. Oman J Ophthalmol. 2011;4(3):139–141.
- Restrepo JP, Molina MP. Successful treatment of severe nodular scleritis with Adalimumab. Clin Rheumatol. 2010;29(5):559–561.
- De Fidelix TS, Vieira LA, de Freitas D, et al. Biologic therapy for refractory scleritis: a new treatment perspective. Int Ophthalmol. 2015;35(6):903–912.
- Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2012;31(1):90–91.
- Dutta Majumder P, Jayshree DRL, Kaushik V. A case of idiopathic necrotizing scleritis with secondary glaucoma treated successfully with golimumab and Ahmed valve implantation. Indian J Ophthalmol. 2019;67(8):1360–1362.
- Bottin C, Fel A, Butel N, et al. Anakinra in the treatment of patients with refractory scleritis: a pilot study. Ocul Immunol Inflamm. 2018;26(6):915–920.
- Knickelbein JE, Tucker WR, Bhatt N, et al. Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a Phase I/II clinical trial. Am J Ophthalmol. 2016;172:104–110.
- Cunningham ET, Adan A, Nguyen QD, et al. Tocilizumab for the treatment of ocular inflammatory disease. Ocul Immunol Inflamm. 2021;29(1):2–5.
- Shimizu H, Nishioka H. Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis. Scand J Rheumatol. 2017;46(5):418–419.
- Poelman HJ, Van Daele PLA, Rothova A. Successful tocilizumab treatment for scleritis. Ocul Immunol Inflamm. 2020;28(2):285–287.
- Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–6.
- Tode J, Zeuner R, Saeger M, et al. Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis. Acta Ophthalmol. 2015;93(8):e683–4.
- Farhat R, Clavel G, Villeneuve D, et al. Sustained remission with tocilizumab in refractory relapsing polychondritis with ocular involvement: a case series. Ocul Immunol Inflamm. 2021;29(1):9–13.
- Tanaka R, Kaburaki T, Nakahara H, et al. Ocular inflammation associated with relapsing polychondritis in Japanese patients: a review of 11 patients. Int Ophthalmol. 2019;39(11):2649–2659.
- Fabiani C, Sota J, Sainz-de-la-Maza M, et al. New potential weapons for refractory scleritis in the era of targeted therapy. Mediators Inflamm. 2020;2020:8294560.
- Perez-Jacoiste Asin MA, Charles P, Rothschild PR, et al. Ocular involvement in granulomatosis with polyangiitis: a single-center cohort study on 63 patients. Autoimmun Rev. 18(5): 493–500. 2019.
- Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology. 2014;121(10):1885–1891.
- Cao JH, Oray M, Foster CS. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol. 2016;166:207–208.
- Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–1547.
- Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18(3):223–225.
- Onal S, Kazokoglu H, Koc A, et al. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm. 2008;16(5):230–232.
- Caso F, Fiocco U, Costa L, et al. Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. Joint Bone Spine. 2014;81(2):190–192.
- Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology. 2003;110(4):786–789.
- Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53–55.
- Pyare R, Kaushik V, Dutta Majumder P, et al. Tofacitinib in recalcitrant scleritis: first case report from India. Indian J Ophthalmol. 2020;68(9):1988–1990.